Pharmaceutical Sciences
Global

Pharmaceutical Sciences Experts

Leandro Bueno Bergantin


Department of Pharmacology
Federal University of São Paulo
Brazil

Biography

Dr. Bergantin received his academic education at EPM-UNIFESP (Brazil) and UAM (Spain): degree in biomedicine (2008), MSc (2010) and PhD (2014). His research involves cell signaling mediated by Ca2+ and cAMP, skeletal and smooth muscles, peripheral and central nervous systems. His research work solved the enigma of the paradoxical effects produced by Ltype Ca2+ channel blockers (TOP 25 Hottest Articles - Biochemistry, Genetics and Molecular Biology - Cell Calcium - TOP 1 July to September 2013/ TOP 5 October to December 2013/ TOP 1 January to December 2013 full year/TOP 6 January to March 2014). Since 1975, several clinical and experimental studies have reported that acute and chronic administration of L-type Ca2+ channel blockers (CCB), such as nifedipine, produces reduction in arterial pressure associated with a paradoxical increase of sympathetic activity. Despite this sympathetic hyperactivity has been initially attributed to adjust reflex of arterial pressure, the cellular and molecular mechanisms involved in this apparent sympathomimetic effect of the L-type CCB remained unclear for decades. In 2013, Dr. Bergantin and collaborators discovered that this paradoxical increase in sympathetic activity produced by L-type CCB is due to interaction of the Ca2+/cAMP signaling pathways. Then, the pharmacological manipulation of the Ca2+/cAMP interaction produced by combination of the L-type CCB used in the antihypertensive therapy, and cAMP accumulating compounds used in the antidepressive therapy, could represent a potential cardiovascular risk for hypertensive patients due to increase in sympathetic activity. In contrast, this pharmacological manipulation could be a new therapeutic strategy for increasing neurotransmission in psychiatric disorders, and producing neuroprotection in the neurodegenerative diseases (Bergantin and Caricati-Neto, 2016 Eur J Pharmacol; Caricati-Neto et al., 2015 Pharm Res Perspect). Dr. Bergantin has published several articles in international journals, book chapters, and an international book. He is member of 20 editorial boards of international journals. Dr. Bergantin has been frequently invited to be honorable guest (speaker) in international conferences (e.g.: more than 30 invitations in 2016).

Research Interest

Pharmacology, Biomedicine

Global Experts from Brazil

Global Experts in Subject

Share This Profile
Recommended Conferences
  • 12th Asian Biologics and Biosimilars Congress

    August 20-21, 2018 Tokyo, Japan

  • International Conference and Exhibition on Drug Safety & Pharmacovigilance

    August 29-30, 2018 | Toronto, UK

  • 6 th European Biopharma Congress

    September 18-19, 2018 Amsterdam, Netherlands

  • 5th International Conference on Pain Medicine and Pain Management

    October 17-18, 2018 New York, USA

  • 18th World Pharma Congress

    October 18-19, 2018 Warsaw, Poland

  • 13th International Conference on Biosimilars and Biologics

    November 14-15, 2018 Lisbon, Portugal

  • 14th International Conference on Generic Drugs and Biosimilars

    November 15-16, 2018 Berlin, Germany

View more